Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling | Zendy

R. Loch Macdonald | Zendy; Randall T. Higashida | Zendy; E. Keller | Zendy; Stephan A. Mayer | Zendy; Andy Molyneux | Zendy; Andreas Raabe | Zendy; Peter Vajkoczy | Zendy; Isabel Wanke | Zendy; Doris Bach | Zendy; Aline Frey | Zendy; Pegah Nowbakht | Zendy; Sébastiên Roux | Zendy; Neal F. Kassell | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Randomized Trial of Clazosentan in Patients With Aneurysmal Subarachnoid Hemorrhage Undergoing Endovascular Coiling

Author(s) -

R. Loch Macdonald,

Randall T. Higashida,

E. Keller,

Stephan A. Mayer,

Andy Molyneux,

Andreas Raabe,

Peter Vajkoczy,

Isabel Wanke,

Doris Bach,

Aline Frey,

Pegah Nowbakht,

Sébastiên Roux,

Neal F. Kassell

Publication year - 2012

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.111.648980

Subject(s) - medicine , subarachnoid hemorrhage , randomized controlled trial , endovascular coiling , endovascular treatment , stroke (engine) , surgery , aneurysm , mechanical engineering , engineering

Clazosentan, an endothelin receptor antagonist, has been shown to reduce vasospasm after aneurysmal subarachnoid hemorrhage (aSAH). CONSCIOUS-3 assessed whether clazosentan reduced vasospasm-related morbidity and all-cause mortality postaSAH secured by endovascular coiling.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research